These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Paricalcitol and cinacalcet have disparate actions on parathyroid oxyphil cell content in patients with chronic kidney disease. Ritter C; Miller B; Coyne DW; Gupta D; Zheng S; Brown AJ; Slatopolsky E Kidney Int; 2017 Nov; 92(5):1217-1222. PubMed ID: 28750928 [TBL] [Abstract][Full Text] [Related]
4. A case of hyperparathyroidism-associated parkinsonism successfully treated with cinacalcet hydrochloride, a calcimimetic. Ohya Y; Osaki M; Sakai S; Kimura S; Yasuda C; Ago T; Kitazono T; Arakawa S BMC Neurol; 2018 May; 18(1):62. PubMed ID: 29734949 [TBL] [Abstract][Full Text] [Related]
5. A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro. Kawata T; Tokunaga S; Murai M; Masuda N; Haruyama W; Shoukei Y; Hisada Y; Yanagida T; Miyazaki H; Wada M; Akizawa T; Fukagawa M PLoS One; 2018; 13(4):e0195316. PubMed ID: 29614098 [TBL] [Abstract][Full Text] [Related]
13. Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism. Bover J; Ureña P; Ruiz-García C; daSilva I; Lescano P; del Carpio J; Ballarín J; Cozzolino M Clin J Am Soc Nephrol; 2016 Jan; 11(1):161-74. PubMed ID: 26224878 [TBL] [Abstract][Full Text] [Related]
14. New insights into the role of calcium-sensing receptor activation. Cozzolino M; Mazzaferro S; Messa P J Nephrol; 2011; 24 Suppl 18():S38-41. PubMed ID: 21623581 [TBL] [Abstract][Full Text] [Related]
15. Calcimimetic and calcilytic drugs for treating bone and mineral-related disorders. Nemeth EF; Shoback D Best Pract Res Clin Endocrinol Metab; 2013 Jun; 27(3):373-84. PubMed ID: 23856266 [TBL] [Abstract][Full Text] [Related]
16. A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM). Wetmore JB; Gurevich K; Sprague S; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K Clin J Am Soc Nephrol; 2015 Jun; 10(6):1031-40. PubMed ID: 25904755 [TBL] [Abstract][Full Text] [Related]
18. [The use of Cinacalcet in chronic kidney disease: a case report]. Russo R; Argentino G; Maresca ID; Sannino G; Memoli A; Memoli B G Ital Nefrol; 2015; 32(4):. PubMed ID: 26252263 [TBL] [Abstract][Full Text] [Related]
19. The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis: The EVOLVE Trial. Floege J; Kubo Y; Floege A; Chertow GM; Parfrey PS Clin J Am Soc Nephrol; 2015 May; 10(5):800-7. PubMed ID: 25887067 [TBL] [Abstract][Full Text] [Related]
20. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism. Sprague SM; Wetmore JB; Gurevich K; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K Clin J Am Soc Nephrol; 2015 Jun; 10(6):1021-30. PubMed ID: 25873267 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]